Spero Therapeutics, Inc. Payments for Restructuring
Spero Therapeutics, Inc. (SPRO) reported Payments for Restructuring of $714.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-03-26
- Spero Therapeutics, Inc. payments for restructuring for the quarter ending 2025-12-31 was $0.00.
- Spero Therapeutics, Inc. payments for restructuring for the quarter ending 2025-09-30 was $83.00K.
- Spero Therapeutics, Inc. payments for restructuring for the quarter ending 2025-06-30 was $142.00K.
- Spero Therapeutics, Inc. payments for restructuring for the quarter ending 2025-03-31 was $489.00K.
- Spero Therapeutics, Inc. payments for restructuring for fiscal 2025 was $714.00K, a 69.60% increase from fiscal 2024.
- Spero Therapeutics, Inc. payments for restructuring for fiscal 2024 was $421.00K, a 2.93% increase from fiscal 2023.
- Spero Therapeutics, Inc. payments for restructuring for fiscal 2023 was $409.00K, a 94.69% decline from fiscal 2022.
- Spero Therapeutics, Inc. payments for restructuring for fiscal 2022 was $7.70M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $83.00K derived: sum of 2 quarters · filed 2026-03-26 | $225.00K derived: sum of 3 quarters · filed 2026-03-26 | $714.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $225.00K derived: sum of 2 quarters · filed 2025-11-13 | $714.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $631.00K 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $489.00K 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $421.00K 10-K · filed 2025-03-27 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $409.00K 10-K · filed 2024-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $409.00K 10-Q · filed 2023-11-13 | $861.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $409.00K 10-Q · filed 2023-08-10 | $861.00K derived: sum of 3 quarters · filed 2023-08-10 | $2.06M derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $409.00K 10-Q · filed 2023-05-11 | $861.00K derived: sum of 2 quarters · filed 2023-05-11 | $2.06M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2022-12-31 | $452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.65M derived: sum of 2 quarters · filed 2023-03-30 | $7.70M 10-K · filed 2023-03-30 | |
| 2022-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $7.25M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $6.05M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |